Category: Corporate NewsBy Rameda Admin7 أغسطس، 2024 Author: Rameda Admin Post navigationPreviousPrevious post:Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceNextNext post:Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketRelated Postsأول صفقات راميدا في 2025 إضافة استراتيجية لمحفظة أدوية الأمراض المزمنة7 يوليو، 2025إفصاح توزيع أرباح قياسية7 يوليو، 2025Rameda One-Pager 1Q2513 مايو، 2025Rameda Completes Largest Acquisition to Date30 سبتمبر، 2024Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical Market9 سبتمبر، 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intolerance28 مايو، 2024
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical Market9 سبتمبر، 2024
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intolerance28 مايو، 2024
